Stock Taper Q4 Revenue: $249 million, up 7% from $232 million in Q4 2025.
Earnings Per Share (EPS): $0.61, an increase from $0.51 year-over-year.
Fiscal Year 2026 Revenue: $959 million, a 7% increase from $896 million in FY 2025.
Fiscal Year EPS: $2.14, up 17% from $1.83 in FY 2025.
Net Income: $110 million for FY 2026, a 14% increase from $95 million in FY 2025.
Operating Margin: Improved to 15%, up 1.4% from FY 2025.
Free Cash Flow: $66 million, a $7 million increase from FY 2025.
Cash Balance: $233 million at fiscal year-end.
Share Repurchase: 872,744 shares repurchased in FY 2026 for $56 million; total repurchased shares since inception: 115.3 million (69% of total shares outstanding).
Network Solutions: Strong performance with double-digit revenue and profit growth, driven by new large payer engagements and elevated post-payment recoveries.
Patient Management: Low single-digit revenue growth, focusing on operational efficiency and service quality improvements.
New Bookings: Increased by 56% year-over-year, with RFP activity up 20%, indicating a robust pipeline.
Technological Investments: Continued focus on AI and automation to enhance service delivery and operational efficiency.
Market Trends: Shift towards proactive payment accuracy and cost management models, with CorVel's CERIS platform positioned to capitalize on this trend.
Anticipated ongoing revenue and profit growth from new multiyear partnerships with top national payers.
Expected productivity gains through automation and AI enhancements, which should improve operating leverage and reduce manual processes.
Continued focus on expanding prepaid solutions to create a more predictable revenue model.
Increased Effective Tax Rate: The rise in the effective tax rate impacted earnings growth, although some effects were mitigated by business growth.
Personnel Levels: Increased personnel to support service delivery may lead to higher costs until automation and AI are fully implemented.
Market Pressures: The healthcare environment is facing rising claims severity and complexity, which could challenge operational efficiency and cost management.
No questions were raised during the call, indicating either a lack of immediate concerns from analysts or a strong confidence in the reported results and strategic direction. Overall, CorVel demonstrated solid financial performance and strategic positioning in a challenging healthcare environment, with a focus on technology and proactive solutions to drive future growth.
SOURCE: Q4 2026 EARNINGS CALL TRANSCRIPT